Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.

Abstract

NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream signaling, and tumorigenesis. Targeting ERBBs, therefore, represents a therapeutic strategy for these cancers. We investigated zenocutuzumab (Zeno; MCLA-128), an antibody-dependent cellular cytotoxicity-enhanced anti-HER2xHER3 bispecific antibody, in NRG1 fusion-positive isogenic and patient-derived cell lines and xenograft models. Zeno inhibited HER3 and AKT phosphorylation, induced expression of apoptosis markers, and inhibited growth. Three patients with chemotherapy-resistant NRG1 fusion-positive metastatic cancer were treated with Zeno. Two patients with ATP1B1-NRG1-positive pancreatic cancer achieved rapid symptomatic, biomarker, and radiographic responses and remained on treatment for over 12 months. A patient with CD74-NRG1-positive non-small cell lung cancer who had progressed on six prior lines of systemic therapy, including afatinib, responded rapidly to treatment with a partial response. Targeting HER2 and HER3 simultaneously with Zeno is a novel therapeutic paradigm for patients with NRG1 fusion-positive cancers.

SIGNIFICANCE:

NRG1 rearrangements encode chimeric ligands that activate the ERBB receptor tyrosine kinase family. Here we show that targeting HER2 and HER3 simultaneously with the bispecific antibody Zeno leads to durable clinical responses in patients with NRG1 fusion-positive cancers and is thus an effective therapeutic strategy. This article is highlighted in the In This Issue feature, p. 1171.

• Authors: Alison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J Sisso, Marissa S Mattar, Allan J W Lui, Morana Vojnic, Sara H Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, Marie N O'Connor, Cecile A W Geuijen, Ron C J Schackmann, Jeroen J Lammerts van Bueren, Ernesto Wasserman, Elisa de Stanchina, Eileen M O'Reilly, Marc Ladanyi, Alexander Drilon, Romel Somwar
• Journal: Cancer discovery (Cancer Discov) Vol. 12 Issue 5 Pg. 1233-1247 (05 02 2022) ISSN: 2159-8290 [Electronic] United States
• PMID: 35135829 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: ©2022 The Authors; Published by the American Association for Cancer Research.

Chemical References

• Antibodies, Bispecific
• Immunoglobulin G
• NRG1 protein, human
• Neuregulin-1
• zenocutuzumab
• Receptor, ErbB-2
• Receptor, ErbB-3

Topics

• Antibodies, Bispecific
• Carcinogenesis (genetics)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics)
• Cell Line, Tumor
• Gene Rearrangement
• Humans
• Immunoglobulin G
• Lung Neoplasms (genetics)
• Neuregulin-1 (genetics)
• Receptor, ErbB-2
• Receptor, ErbB-3 (genetics, metabolism)